Copyright Reports & Markets. All rights reserved.

Global and United States Constrained Peptide Drugs Market Report & Forecast 2022-2028

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Constrained Peptide Drugs Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Introduction
    • 1.2 Global Constrained Peptide Drugs Outlook 2017 VS 2022 VS 2028
      • 1.2.1 Global Constrained Peptide Drugs Market Size for the Year 2017-2028
      • 1.2.2 Global Constrained Peptide Drugs Market Size for the Year 2017-2028
    • 1.3 Constrained Peptide Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
      • 1.3.1 The Market Share of United States Constrained Peptide Drugs in Global, 2017 VS 2022 VS 2028
      • 1.3.2 The Growth Rate of Constrained Peptide Drugs Market Size, United States VS Global, 2017 VS 2022 VS 2028
    • 1.4 Constrained Peptide Drugs Market Dynamics
      • 1.4.1 Constrained Peptide Drugs Industry Trends
      • 1.4.2 Constrained Peptide Drugs Market Drivers
      • 1.4.3 Constrained Peptide Drugs Market Challenges
      • 1.4.4 Constrained Peptide Drugs Market Restraints
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Constrained Peptide Drugs by Type

    • 2.1 Constrained Peptide Drugs Market Segment by Type
      • 2.1.1 Cyclic Peptides
      • 2.1.2 Disulfide-Rich Peptides (DRPs)
    • 2.2 Global Constrained Peptide Drugs Market Size by Type (2017, 2022 & 2028)
    • 2.3 Global Constrained Peptide Drugs Market Size by Type (2017-2028)
    • 2.4 United States Constrained Peptide Drugs Market Size by Type (2017, 2022 & 2028)
    • 2.5 United States Constrained Peptide Drugs Market Size by Type (2017-2028)

    3 Constrained Peptide Drugs by Application

    • 3.1 Constrained Peptide Drugs Market Segment by Application
      • 3.1.1 Hospital
      • 3.1.2 Institute of Biology
      • 3.1.3 Others
    • 3.2 Global Constrained Peptide Drugs Market Size by Application (2017, 2022 & 2028)
    • 3.3 Global Constrained Peptide Drugs Market Size by Application (2017-2028)
    • 3.4 United States Constrained Peptide Drugs Market Size by Application (2017, 2022 & 2028)
    • 3.5 United States Constrained Peptide Drugs Market Size by Application (2017-2028)

    4 Global Constrained Peptide Drugs Competitor Landscape by Company

    • 4.1 Global Constrained Peptide Drugs Market Size by Company
      • 4.1.1 Top Global Constrained Peptide Drugs Companies Ranked by Revenue (2021)
      • 4.1.2 Global Constrained Peptide Drugs Revenue by Player (2017-2022)
    • 4.2 Global Constrained Peptide Drugs Concentration Ratio (CR)
      • 4.2.1 Constrained Peptide Drugs Market Concentration Ratio (CR) (2017-2022)
      • 4.2.2 Global Top 5 and Top 10 Largest Companies of Constrained Peptide Drugs in 2021
      • 4.2.3 Global Constrained Peptide Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    • 4.3 Global Constrained Peptide Drugs Headquarters, Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Type
      • 4.3.1 Global Constrained Peptide Drugs Headquarters and Area Served
      • 4.3.2 Global Constrained Peptide Drugs Companies Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) Type
      • 4.3.3 Date of International Companies Enter into Constrained Peptide Drugs Market
    • 4.4 Companies Mergers & Acquisitions, Expansion Plans
    • 4.5 United States Constrained Peptide Drugs Market Size by Company
      • 4.5.1 Top Constrained Peptide Drugs Players in United States, Ranked by Revenue (2021)
      • 4.5.2 United States Constrained Peptide Drugs Revenue by Players (2020, 2021 & 2022)

    5 Global Constrained Peptide Drugs Market Size by Region

    • 5.1 Global Constrained Peptide Drugs Market Size by Region: 2017 VS 2022 VS 2028
    • 5.2 Global Constrained Peptide Drugs Market Size by Region (2017-2028)
      • 5.2.1 Global Constrained Peptide Drugs Market Size by Region: 2017-2022
      • 5.2.2 Global Constrained Peptide Drugs Market Size by Region (2023-2028)

    6 Segment in Region Level & Country Level

    • 6.1 North America
      • 6.1.1 North America Constrained Peptide Drugs Market Size YoY Growth 2017-2028
      • 6.1.2 North America Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.1.3 United States
      • 6.1.4 Canada
    • 6.2 Asia-Pacific
      • 6.2.1 Asia-Pacific Constrained Peptide Drugs Market Size YoY Growth 2017-2028
      • 6.2.2 Asia-Pacific Constrained Peptide Drugs Market Facts & Figures by Region (2017, 2022 & 2028)
      • 6.2.3 China
      • 6.2.4 Japan
      • 6.2.5 South Korea
      • 6.2.6 India
      • 6.2.7 Australia
      • 6.2.8 China Taiwan
      • 6.2.9 Indonesia
      • 6.2.10 Thailand
      • 6.2.11 Malaysia
    • 6.3 Europe
      • 6.3.1 Europe Constrained Peptide Drugs Market Size YoY Growth 2017-2028
      • 6.3.2 Europe Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.3.3 Germany
      • 6.3.4 France
      • 6.3.5 U.K.
      • 6.3.6 Italy
      • 6.3.7 Russia
    • 6.4 Latin America
      • 6.4.1 Latin America Constrained Peptide Drugs Market Size YoY Growth 2017-2028
      • 6.4.2 Latin America Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.4.3 Mexico
      • 6.4.4 Brazil
      • 6.4.5 Argentina
      • 6.4.6 Colombia
    • 6.5 Middle East and Africa
      • 6.5.1 Middle East and Africa Constrained Peptide Drugs Market Size YoY Growth 2017-2028
      • 6.5.2 Middle East and Africa Constrained Peptide Drugs Market Facts & Figures by Country (2017, 2022 & 2028)
      • 6.5.3 Turkey
      • 6.5.4 Saudi Arabia
      • 6.5.5 UAE

    7 Company Profiles

    • 7.1 Aileron Therapeutics, Inc
      • 7.1.1 Aileron Therapeutics, Inc Company Details
      • 7.1.2 Aileron Therapeutics, Inc Business Overview
      • 7.1.3 Aileron Therapeutics, Inc Constrained Peptide Drugs Introduction
      • 7.1.4 Aileron Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.1.5 Aileron Therapeutics, Inc Recent Development
    • 7.2 Bicycle Therapeutics, PLC
      • 7.2.1 Bicycle Therapeutics, PLC Company Details
      • 7.2.2 Bicycle Therapeutics, PLC Business Overview
      • 7.2.3 Bicycle Therapeutics, PLC Constrained Peptide Drugs Introduction
      • 7.2.4 Bicycle Therapeutics, PLC Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.2.5 Bicycle Therapeutics, PLC Recent Development
    • 7.3 Polyphor Limited
      • 7.3.1 Polyphor Limited Company Details
      • 7.3.2 Polyphor Limited Business Overview
      • 7.3.3 Polyphor Limited Constrained Peptide Drugs Introduction
      • 7.3.4 Polyphor Limited Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.3.5 Polyphor Limited Recent Development
    • 7.4 Protagonist Therapeutics, Inc
      • 7.4.1 Protagonist Therapeutics, Inc Company Details
      • 7.4.2 Protagonist Therapeutics, Inc Business Overview
      • 7.4.3 Protagonist Therapeutics, Inc Constrained Peptide Drugs Introduction
      • 7.4.4 Protagonist Therapeutics, Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.4.5 Protagonist Therapeutics, Inc Recent Development
    • 7.5 Santhera Pharmaceuticals Holding
      • 7.5.1 Santhera Pharmaceuticals Holding Company Details
      • 7.5.2 Santhera Pharmaceuticals Holding Business Overview
      • 7.5.3 Santhera Pharmaceuticals Holding Constrained Peptide Drugs Introduction
      • 7.5.4 Santhera Pharmaceuticals Holding Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.5.5 Santhera Pharmaceuticals Holding Recent Development
    • 7.6 Union Chimique Belge S.A. (UCB)
      • 7.6.1 Union Chimique Belge S.A. (UCB) Company Details
      • 7.6.2 Union Chimique Belge S.A. (UCB) Business Overview
      • 7.6.3 Union Chimique Belge S.A. (UCB) Constrained Peptide Drugs Introduction
      • 7.6.4 Union Chimique Belge S.A. (UCB) Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.6.5 Union Chimique Belge S.A. (UCB) Recent Development
    • 7.7 Pepscan Therapeutics B.V.
      • 7.7.1 Pepscan Therapeutics B.V. Company Details
      • 7.7.2 Pepscan Therapeutics B.V. Business Overview
      • 7.7.3 Pepscan Therapeutics B.V. Constrained Peptide Drugs Introduction
      • 7.7.4 Pepscan Therapeutics B.V. Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.7.5 Pepscan Therapeutics B.V. Recent Development
    • 7.8 Pepticom Ltd.
      • 7.8.1 Pepticom Ltd. Company Details
      • 7.8.2 Pepticom Ltd. Business Overview
      • 7.8.3 Pepticom Ltd. Constrained Peptide Drugs Introduction
      • 7.8.4 Pepticom Ltd. Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.8.5 Pepticom Ltd. Recent Development
    • 7.9 PeptiDream, Inc.
      • 7.9.1 PeptiDream, Inc. Company Details
      • 7.9.2 PeptiDream, Inc. Business Overview
      • 7.9.3 PeptiDream, Inc. Constrained Peptide Drugs Introduction
      • 7.9.4 PeptiDream, Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.9.5 PeptiDream, Inc. Recent Development
    • 7.10 CPC Scientific Inc.
      • 7.10.1 CPC Scientific Inc. Company Details
      • 7.10.2 CPC Scientific Inc. Business Overview
      • 7.10.3 CPC Scientific Inc. Constrained Peptide Drugs Introduction
      • 7.10.4 CPC Scientific Inc. Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.10.5 CPC Scientific Inc. Recent Development
    • 7.11 Creative Peptides
      • 7.11.1 Creative Peptides Company Details
      • 7.11.2 Creative Peptides Business Overview
      • 7.11.3 Creative Peptides Constrained Peptide Drugs Introduction
      • 7.11.4 Creative Peptides Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.11.5 Creative Peptides Recent Development
    • 7.12 Bio-Synthesis Inc
      • 7.12.1 Bio-Synthesis Inc Company Details
      • 7.12.2 Bio-Synthesis Inc Business Overview
      • 7.12.3 Bio-Synthesis Inc Constrained Peptide Drugs Introduction
      • 7.12.4 Bio-Synthesis Inc Revenue in Constrained Peptide Drugs Business (2017-2022)
      • 7.12.5 Bio-Synthesis Inc Recent Development

    8 Research Findings and Conclusion

      9 Appendix

      • 9.1 Research Methodology
        • 9.1.1 Methodology/Research Approach
        • 9.1.2 Data Source
      • 9.2 Author Details

      Summary:
      Market Analysis and Insights: Global and United States Constrained Peptide Drugs Market
      This report focuses on global and United States Constrained Peptide Drugs market, also covers the segmentation data of other regions in regional level and county level.
      Due to the COVID-19 pandemic, the global Constrained Peptide Drugs market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Cyclic Peptides accounting for % of the Constrained Peptide Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Hospital was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
      In United States the Constrained Peptide Drugs market size is expected to grow from US$ million in 2021 to US$ million by 2028, at a CAGR of % during the forecast period 2022-2028.
      Global Constrained Peptide Drugs Scope and Market Size
      Constrained Peptide Drugs market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Constrained Peptide Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
      For United States market, this report focuses on the Constrained Peptide Drugs market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
      Segment by Type, the Constrained Peptide Drugs market is segmented into
      Cyclic Peptides
      Disulfide-Rich Peptides (DRPs)
      Segment by Application, the Constrained Peptide Drugs market is segmented into
      Hospital
      Institute of Biology
      Others
      Regional and Country-level Analysis
      North America
      United States
      Canada
      Europe
      Germany
      France
      U.K.
      Italy
      Russia
      Asia-Pacific
      China
      Japan
      South Korea
      India
      Australia
      China Taiwan
      Indonesia
      Thailand
      Malaysia
      Latin America
      Mexico
      Brazil
      Argentina
      Colombia
      Middle East & Africa
      Turkey
      Saudi Arabia
      UAE
      Competitive Landscape and Constrained Peptide Drugs Market Share Analysis
      Constrained Peptide Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2017-2022. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2017-2022. Details included are company description, major business, company total revenue and the sales, revenue generated in Constrained Peptide Drugs business, the date to enter into the Constrained Peptide Drugs market, Revenue in Constrained Peptide Drugs Business (2017-2022) & (US$ Million) introduction, recent developments, etc.
      The major vendors covered:
      Aileron Therapeutics, Inc
      Bicycle Therapeutics, PLC
      Polyphor Limited
      Protagonist Therapeutics, Inc
      Santhera Pharmaceuticals Holding
      Union Chimique Belge S.A. (UCB)
      Pepscan Therapeutics B.V.
      Pepticom Ltd.
      PeptiDream, Inc.
      CPC Scientific Inc.
      Creative Peptides
      Bio-Synthesis Inc
      Buy now